Détails sur le projet
Description
This is a Scientist Development Award for Clinicians to develop expertise
in treatment research with adolescent drug abusers. The theme of this
application is prevention of career addiction through early intervention.
The target group is teenagers using "gateway" (marijuana, hallucinogens
and alcohol) or hard drugs (herein and cocaine). The method is detection,
delineation and treatment of comorbid psychiatric disorders that increase
the risk for career addition. The specific focus is on mood disorders.
Since pilot data already suggest depression is detectable and treatable in
this at-risk population, a double blind placebo-controlled study with
fluoxetine is planned for substance abusing teenagers with unipolar
spectrum disorders (major depression, dysthymia). Mood stabilizing agents
are commonly prescribed in the substance abusing population, but
systematic study is lacking. An open trial of a mood stabilizing agent
(Depakote) is therefore proposed for substance abusing teenagers with
severe mood swings meeting specified screening criteria.
Although there is insufficient time in this grant to perform two clinical
trials and a full family study, carefully collected family history data
and treatment response will be used to develop an algorithm to predict
which patients will benefit from psychopharmacologic intervention. Future
career possibilities include clinical trials testing the derived
predictors, with long-term follow-up and collaboration in family studies.
Statut | Terminé |
---|---|
Date de début/de fin réelle | 9/30/94 → 8/31/00 |
Financement
- National Institute on Drug Abuse
Keywords
- Psiquiatría y salud mental
Empreinte numérique
Explorer les sujets de recherche abordés dans ce projet. Ces étiquettes sont créées en fonction des prix/bourses sous-jacents. Ensemble, ils forment une empreinte numérique unique.